Eduardo Dunayevich

6.1k total citations · 3 hit papers
47 papers, 4.1k citations indexed

About

Eduardo Dunayevich is a scholar working on Psychiatry and Mental health, Pharmacology and Clinical Psychology. According to data from OpenAlex, Eduardo Dunayevich has authored 47 papers receiving a total of 4.1k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Psychiatry and Mental health, 23 papers in Pharmacology and 11 papers in Clinical Psychology. Recurrent topics in Eduardo Dunayevich's work include Schizophrenia research and treatment (15 papers), Pharmacology and Obesity Treatment (9 papers) and Cannabis and Cannabinoid Research (9 papers). Eduardo Dunayevich is often cited by papers focused on Schizophrenia research and treatment (15 papers), Pharmacology and Obesity Treatment (9 papers) and Cannabis and Cannabinoid Research (9 papers). Eduardo Dunayevich collaborates with scholars based in United States, United Kingdom and Australia. Eduardo Dunayevich's co-authors include J. Erickson, Frank L. Greenway, Ken Fujioka, Dennis Dong Hwan Kim, Maria Guttadauria, Paul E. Keck, Raymond A Plodkowski, Sunder Mudaliar, Gary D. Tollefson and Ronald Landbloom and has published in prestigious journals such as The Lancet, Journal of the American College of Cardiology and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Eduardo Dunayevich

46 papers receiving 3.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

2010 706 citations Frank L. Greenway, J. Erickson et al. profile →
A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity‐related risk factors (COR‐II)

2013 463 citations Caroline M. Apovian, Colleen Burns et al. profile →
Dose-Ranging Effect of Adjunctive Oral Cannabidiol vs Placebo on Convulsive Seizure Frequency in Dravet Syndrome

2020 192 citations Ian Miller, Ingrid E. Scheffer et al. profile →

Peers

Countries citing papers authored by Eduardo Dunayevich

Since Specialization

Citations

This map shows the geographic impact of Eduardo Dunayevich's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eduardo Dunayevich with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eduardo Dunayevich more than expected).

Fields of papers citing papers by Eduardo Dunayevich

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eduardo Dunayevich. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eduardo Dunayevich. The network helps show where Eduardo Dunayevich may publish in the future.

Co-authorship network of co-authors of Eduardo Dunayevich

This figure shows the co-authorship network connecting the top 25 collaborators of Eduardo Dunayevich. A scholar is included among the top collaborators of Eduardo Dunayevich based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eduardo Dunayevich. Eduardo Dunayevich is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	INTERACT: a randomized phase 2 study of the DAAO inhibitor luvadaxistat in adults with schizophrenia 2024 ·Schizophrenia Research ·(unknown), Elizabeth Hanson, Nicholas DeMartinis, Mahnaz Asgharnejad, (unknown), Rebecca Evans, (unknown), Eduardo Dunayevich, Jaskaran Singh, Emiliangelo Ratti, Silvana Galderisi	15
2	The D-amino acid oxidase inhibitor luvadaxistat improves mismatch negativity in patients with schizophrenia in a randomized trial 2023 ·Neuropsychopharmacology ·Patricio O’Donnell, (unknown), (unknown), Mahnaz Asgharnejad, Xiaoming Du, Ann Summerfelt, H. Lü, Lin Xu, Jens R. Wendland, Eduardo Dunayevich, Derek L. Buhl, Robert E. Litman, William P. Hetrick, L. Elliot Hong, Laura Rosen	34
3	Cannabidiol (CBD; 10 And 20 MG/KG/Day) Significantly Reduces Convulsive Seizure Frequency In Children And Adolescents With Dravet Syndrome: Results Of A Dose-Ranging, Multi-Center, Randomised, Double-Blind, Placebo-Controlled Trial (GWPCARE2) 2019 ·Epilepsia ·Ian Miller, Ingrid E. Scheffer, Boudewijn Gunning, Rocío Sánchez‐Carpintero, António Gil‐Nagel, (unknown), Russell P. Saneto, Daniel Checketts, (unknown), Eduardo Dunayevich, Volker Knappertz	1
4	Psychiatric adverse events and effects on mood with prolonged-release naltrexone/bupropion combination therapy: a pooled analysis 2019 ·International Journal of Obesity ·F. Xavier Pi‐Sunyer, Caroline M. Apovian, Susan L. McElroy, Eduardo Dunayevich, Lisette M. Acevedo, Frank L. Greenway	19
5	Psychometric characteristics of the MATRICS Consensus Cognitive Battery in a large pooled cohort of stable schizophrenia patients 2017 ·Schizophrenia Research ·Anastasia Georgiades, Vicki G. Davis, Alexandra S. Atkins, Anzalee Khan, (unknown), Antony Loebel, George M. Haig, Dana Hilt, Eduardo Dunayevich, Daniel Umbricht, Michael Sand, Richard S.E. Keefe	37
6	Efficacy and safety of the glycine transporter type-1 inhibitor AMG 747 for the treatment of negative symptoms associated with schizophrenia 2016 ·Schizophrenia Research ·Eduardo Dunayevich, Robert W. Buchanan, Chaoyin Chen, Jun Yang, Jon Nilsen, Julie Dietrich, Hong Sun, Stephen R. Marder	30
7	Effort-Based Decision-Making Paradigms for Clinical Trials in Schizophrenia: Part 1—Psychometric Characteristics of 5 Paradigms 2015 ·Schizophrenia Bulletin ·L. Felice Reddy, William P. Horan, Deanna M. Barch, Robert W. Buchanan, Eduardo Dunayevich, James M. Gold, (unknown), Stephen R. Marder, Michael T. Treadway, Jonathan K. Wynn, Jared W. Young, Michael F. Green	132
8	Effort-Based Decision-Making Paradigms for Clinical Trials in Schizophrenia: Part 2—External Validity and Correlates 2015 ·Schizophrenia Bulletin ·William P. Horan, L. Felice Reddy, Deanna M. Barch, Robert W. Buchanan, Eduardo Dunayevich, James M. Gold, (unknown), Jonathan K. Wynn, Jared W. Young, Michael F. Green	98
9	Restrictive symptomatic inclusion criteria create barriers to clinical research in schizophrenia negative symptoms: An analysis of the CATIE dataset 2014 ·European Neuropsychopharmacology ·Eduardo Dunayevich, (unknown), Stephen R. Marder, Jonathan Rabinowitz	5
10	Naltrexone/Bupropion Combination Therapy in Overweight or Obese Patients With Major Depressive Disorder 2013 ·The Primary Care Companion For CNS Disorders ·Susan L. McElroy, Anna I. Guerdjikova, Dennis Dong Hwan Kim, Colleen Burns, (unknown), Ronald Landbloom, Eduardo Dunayevich	33
11	Effect of combined naltrexone and bupropion therapy on the brain’s reactivity to food cues 2013 ·International Journal of Obesity ·Gou‐Jen Wang, Dardo Tomasi, Nora D. Volkow, (unknown), Frank Telang, Elisabeth C. Caparelli, Eduardo Dunayevich	65
12	Case Reports of Postmarketing Adverse Event Experiences With Olanzapine Intramuscular Treatment in Patients With Agitation 2010 ·The Journal of Clinical Psychiatry ·Stephen R. Marder, (unknown), Eduardo Dunayevich, Jamie Karagianis, (unknown), (unknown), Mary Anne Dellva, Janice Carlson, Patrizia Cavazzoni, Robert W. Baker	39
13	Bayesian adaptive non-inferiority with safety assessment: Retrospective case study to highlight potential benefits and limitations of the approach 2008 ·Journal of Psychiatric Research ·(unknown), Stacy Lindborg, John W. Seaman, Robert A. Baker, Eduardo Dunayevich, Alan Breier	2
14	All-Cause Treatment Discontinuation in Schizophrenia During Treatment With Olanzapine Relative to Other Antipsychotics 2007 ·Journal of Clinical Psychopharmacology ·Charles M. Beasley, Virginia L. Stauffer, Hong Liu‐Seifert, Cindy C. Taylor, Eduardo Dunayevich, John M. Davis	35
15	Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial 2007 ·International Clinical Psychopharmacology ·James T. Hartford, Susan G. Kornstein, Michael R. Liebowitz, Teresa A. Pigott, James Russell, Michael J. Detke, Daniel Walker, Susan Ball, Eduardo Dunayevich, (unknown), J. Erickson	99
16	Efficacy and Tolerability of an mGlu2/3 Agonist in the Treatment of Generalized Anxiety Disorder 2007 ·Neuropsychopharmacology ·Eduardo Dunayevich, J. Erickson, Louise R. Levine, Ronald Landbloom, Darryle D. Schoepp, Gary D. Tollefson	147
17	A retrospective comparison of cumulative time spent in remission during treatment with olanzapine or risperidone among patients with schizophrenia 2005 ·Schizophrenia Research ·G. Sethuraman, Chris Taylor, (unknown), Eduardo Dunayevich	23
18	Medical and productivity costs of anxiety disorders: Case control study 2004 ·Depression and Anxiety ·Martin Marciniak, Maureen J. Lage, Ronald Landbloom, Eduardo Dunayevich, Lee Bowman	70
19	A pilot study of rapid lithium administration in the treatment of acute mania 2001 ·Bipolar Disorders ·Paul E. Keck, S M Strakowski, J.M. Hawkins, Eduardo Dunayevich, Karen C. Tugrul, Jerry A. Bennett, Susan L. McElroy	15
20	Prevalence and description of psychotic features in bipolar mania 2000 ·Current Psychiatry Reports ·Eduardo Dunayevich, Paul E. Keck	135

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact